SCHEMBL3522063

SCHEMBL3522063

O=c1c(Br)c(OCc2ccc(F)cc2)ncn1Cc1cccnc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MAPK14 Q16539 6/20 0.49
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.43
CNOT7 Q9UIV1 1/20 0.42
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HIF1A Q16665 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
LRRK2 Q5S007 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521867 0.88 MAPK14 (0.53) SMN1; SMN2MAPK14L3MBTL1KDM4EPOLB
SCHEMBL3522839 0.87 MAPK14 (0.57) PKMSMN1; SMN2MAPK14KDM4ELMNA
SCHEMBL3527861 0.87 MAPK14 (0.54) PKMSMN1; SMN2MAPK14L3MBTL1KDM4E
SCHEMBL3521216 0.86 MAPK14 (0.52) PKMSMN1; SMN2MAPK14L3MBTL1KDM4E
SCHEMBL3521534 0.84 MAPK14 (0.67) SMN1; SMN2MAPK14KDM4EPOLBLMNA
SCHEMBL3520846 0.83 MAPK14 (0.65) PKMSMN1; SMN2MAPK14KDM4ELMNA
SCHEMBL3521487 0.83 PKM (0.44) PKMSMN1; SMN2MAPK14L3MBTL1KDM4E
SCHEMBL4474704 0.83 MAPK14 (0.71) PKMSMN1; SMN2MAPK14LRRK2
SCHEMBL3521789 0.82 MAPK14 (0.50) SMN1; SMN2MAPK14L3MBTL1KDM4ELMNA
SCHEMBL3522118 0.82 MAPK14 (0.47) SMN1; SMN2MAPK14L3MBTL1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795271-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2010-09-14 US disclosed
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES PFIZER INC 2009-12-10 US disclosed
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES PHARMACIA CORPORATION (US) 2007-07-19 US disclosed
US-7183287-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2007-02-27 US disclosed
US-20040242608-A1 Substituted pyrimidinones PHARMACIA LLC 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 PKM 994/4885SMN1; SMN2 912/4885MAPK14 38/4885
US-20040242608-A1 Substituted pyrimidinones MAPK1, MAPK7, MAP3K8 PKM 1090/4885SMN1; SMN2 746/4885MAPK14 29/4885
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 PKM 994/4885SMN1; SMN2 912/4885MAPK14 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.